Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.80 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3690418 | 1.00 | USP2 (0.80) | USP2POLBGAAHTTLMNA | |
| SCHEMBL655768 | 0.98 | USP2 (0.76) | USP2POLBGAAHTTLMNA | |
| SCHEMBL78283 | 0.94 | USP2 (0.69) | USP2POLBGAAHTTALDH1A1 | |
| SCHEMBL11306227 | 0.90 | PKM (0.69) | USP2POLBHTTALDH1A1PKM | |
| SCHEMBL29764367 | 0.84 | USP2 (0.80) | USP2POLBGAAHTTLMNA | |
| SCHEMBL11936028 | 0.82 | USP2 (0.54) | USP2POLBALDH1A1MEN1KMT2A | |
| SCHEMBL30004987 | 0.82 | MEN1 (0.60) | USP2HTTLMNAALDH1A1PKM | |
| SCHEMBL6557849 | 0.81 | USP2 (0.53) | USP2POLBGAALMNAALDH1A1 | |
| SCHEMBL19302897 | 0.81 | ALDH1A1 (0.81) | GAAHTTLMNAALDH1A1PKM | |
| SCHEMBL11510345 | 0.81 | MAPT (0.69) | USP2ALDH1A1PKMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2363393-B1 | Compounds and compositions as hedgehog pathway modulators | NOVARTIS AG (CH) | 2015-08-12 | — | — | EP | claimed |
| US-20120196849-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2012-08-02 | — | — | US | claimed |
| US-20100197659-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS | IRM LLC (BM) | 2010-08-05 | — | — | US | claimed |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-08-13 | — | — | US | claimed |
| CN-101437800-A | Compounds and compositions as HEDGEHOG pathway modulators | IRM LLC (BM) | 2009-05-20 | — | — | CN | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| JP-2007523865-A | — | — | 2007-08-23 | — | — | JP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| US-7129235-B2 | Amides useful for treating pain | ABBOTT LABORATORIES (US) | 2006-10-31 | — | — | US | claimed |
| EP-1646621-A2 | NOVEL AZAHETEROCYCLIC AMIDES USEFUL FOR TREATING PAIN | Abbott Laboratories (US) | 2006-04-19 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-20050080095-A1 | administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I | ABBVIE INC. | 2005-04-14 | — | — | US | claimed |
| WO-2005007642-A2 | NOVEL AZAHETEROCYCLIC AMIDES USEFUL FOR TREATING PAIN | ABBOTT LABORATORIES (US) | 2005-01-27 | — | — | WO | claimed |
| EP-4719413-A1 | INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF | Animol Discovery, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260092070-A1 | INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF | ANIMOL DISCOVERY INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4067354-B1 | NOVEL TRIAZOLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | DAEWOONG PHARMACEUTICAL CO LTD (KR) | 2025-10-22 | — | — | EP | disclosed |
| US-4871843-A | TREATMENT OF NERVOUS SYSTEM DISORDERS WITH ANXIETY | DROPIC-SOCIETE CIVILE DE GESTION DE DROITS DE PROPRIETE INDUSTRIELLE (FR) | 1989-10-03 | — | — | US | disclosed |
| US-4760062-A | Anxiolytic agent | DROPIC, SOCIETE CIVILE DE GESTION DE DROITS DE PROPRIETE INDUSTRIELLE (FR) | 1988-07-26 | — | — | US | disclosed |
| EP-0138720-A2 | N-cyclisized benzenesulfone amides, process for their preparation and their use as active substances in pharmaceutical compositions | DROPIC Société Civile de Gestion de Droit de Propriété Industrielle CHOAY (FR) | 1985-04-24 | — | — | EP | disclosed |
| US-4014647-A | DISPERSE DYES CONTAINING SULFONAMIDE GROUPS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197659-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS | GLI1, SHH, GLI2 | USP2 1239/4885POLB 4636/4885GAA 2972/4885 |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | USP2 1793/4885POLB 4389/4885GAA 2406/4885 |
| US-20050080095-A1 | administering a therapeuitcally effective amount of 3'-(trifluoromethyl)-N-{4-[(trifluoromethyl)sulfonyl]phenyl}-3,6-dihydro-2H-1,2'-bipyridine-4-carboxamide; antagonists of vanilloid receptor subtype I | TRPV1, OPRL1, TRPV6 | USP2 4473/4885POLB 4274/4885GAA 2594/4885 |
| US-20120196849-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | USP2 1793/4885POLB 4389/4885GAA 2406/4885 |
| US-20260092070-A1 | INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF | JAK1, JAK3, JAK2 | USP2 771/4885POLB 4357/4885GAA 3881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.